Suppr超能文献

载脂蛋白 E 的两个相邻结构域(141-150 和 151-160)与一个 A 类两亲性螺旋肽共价连接,表现出相反的动脉粥样硬化作用。

Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects.

机构信息

Atherosclerosis Research Unit and Department of Medicine, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

出版信息

Atherosclerosis. 2010 Dec;213(2):449-57. doi: 10.1016/j.atherosclerosis.2010.09.030. Epub 2010 Oct 27.

Abstract

OBJECTIVE

We recently described anti-atherogenic properties of the dual domain peptide Ac-hE18A-NH(2) derived by covalently linking the heparin binding domain 141-150 of apoE to 18A, a class A amphipathic helical peptide. In this paper we have compared the properties of Ac-hE18A-NH(2) with the non-heparin binding 151-160 region of apoE linked to 18A (Ac-nhE18A-NH(2)).

METHODS AND RESULTS

Both peptides were highly helical in solution and in association with lipids. Ac-hE18A-NH(2) and not Ac-nhE18A-NH(2) enhanced uptake of low density lipoprotein (LDL) in HepG2 cells. While Ac-hE18A-NH(2) retarded the electrophoretic mobility of LDL, Ac-nhE18A-NH(2) slightly enhanced mobility. Ac-hE18A-NH(2) reduced monocyte association with endothelial cells, while Ac-nhE18A-NH(2) increased it. Ac-hE18A-NH(2) also reduced lipid hydroperoxide content of LDL while Ac-nhE18A-NH(2) increased it. A single administration of Ac-hE18A-NH(2) (100 μg/mouse) into apoE null mice dramatically reduced cholesterol (from 600 mg/dL to 180 mg/dL at 5 min and to 60 mg/dL at 5h) while Ac-nhE18A-NH(2) had no effect. Administration (100 μg/mouse/day, three days a week) into apoE null mice for six weeks showed Ac-hE18A-NH(2) group having a moderate aortic sinus lesion reduction compared with the control group (-15.1%), while the Ac-nhE18A-NH(2) administered group had increased lesion area (+33.0% vs controls and 36.1% vs Ac-hE18A-NH(2)). Plasma from mice administered Ac-hE18A-NH(2) for six weeks showed a significant reduction in plasma cholesterol and triglyceride levels and increase in paraoxonase-1 (PON-1) activity compared to controls, while Ac-nhE18A-NH(2) caused no change in plasma cholesterol and decreased PON-1 activity.

CONCLUSION

It is proposed that Ac-hE18A-NH(2) reduced lesion progression in apoE null mice due to its anti-inflammatory and lipoprotein clearing properties, while Ac-nhE18A-NH(2) exhibited pro-atherogenic effects.

摘要

目的

我们最近描述了由共价连接载脂蛋白 E (apoE) 的肝素结合域 141-150 与 A 类两亲性螺旋肽 18A 衍生的双域肽 Ac-hE18A-NH(2) 的抗动脉粥样硬化特性。在本文中,我们比较了 Ac-hE18A-NH(2) 与连接到 18A 的 apoE 的非肝素结合 151-160 区域 (Ac-nhE18A-NH(2)) 的特性。

方法和结果

两种肽在溶液中和与脂质结合时均具有高度的螺旋性。Ac-hE18A-NH(2) 而非 Ac-nhE18A-NH(2) 增强了 HepG2 细胞对低密度脂蛋白 (LDL) 的摄取。虽然 Ac-hE18A-NH(2) 延缓了 LDL 的电泳迁移率,但 Ac-nhE18A-NH(2) 则略微增强了迁移率。Ac-hE18A-NH(2) 减少了单核细胞与内皮细胞的结合,而 Ac-nhE18A-NH(2) 则增加了结合。Ac-hE18A-NH(2) 还降低了 LDL 中脂质氢过氧化物的含量,而 Ac-nhE18A-NH(2) 则增加了含量。单次给予 apoE 缺失小鼠 100 μg/只 Ac-hE18A-NH(2),可在 5 分钟内将胆固醇从 600 mg/dL 降至 180 mg/dL,5 小时后降至 60 mg/dL,而 Ac-nhE18A-NH(2) 则无此作用。在 apoE 缺失小鼠中每周三次给予 100 μg/只 Ac-hE18A-NH(2),6 周后 Ac-hE18A-NH(2) 组主动脉窦病变面积较对照组减少 15.1%,而 Ac-nhE18A-NH(2) 组病变面积增加 36.1%(与对照组相比增加 33.0%,与 Ac-hE18A-NH(2) 相比增加 36.1%)。与对照组相比,连续 6 周给予 Ac-hE18A-NH(2) 的小鼠血浆胆固醇和甘油三酯水平显著降低,对氧磷酶-1 (PON-1) 活性增加,而 Ac-nhE18A-NH(2) 对血浆胆固醇无影响,且降低了 PON-1 活性。

结论

我们提出,Ac-hE18A-NH(2) 降低了 apoE 缺失小鼠的病变进展,这是由于其抗炎和脂蛋白清除特性,而 Ac-nhE18A-NH(2) 则表现出促动脉粥样硬化作用。

相似文献

1
Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects.
Atherosclerosis. 2010 Dec;213(2):449-57. doi: 10.1016/j.atherosclerosis.2010.09.030. Epub 2010 Oct 27.
2
Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.
Atherosclerosis. 2013 Mar;227(1):58-64. doi: 10.1016/j.atherosclerosis.2012.10.064. Epub 2012 Nov 2.
3
Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
Atherosclerosis. 2012 Oct;224(2):326-31. doi: 10.1016/j.atherosclerosis.2012.05.040. Epub 2012 Jun 23.
5
Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2).
Atherosclerosis. 2010 Jan;208(1):134-41. doi: 10.1016/j.atherosclerosis.2009.07.019. Epub 2009 Jul 15.
8
Apolipoprotein E mimetics and cholesterol-lowering properties.
Am J Cardiovasc Drugs. 2011 Dec 1;11(6):371-81. doi: 10.2165/11594190-000000000-00000.
9
Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.
Protein Pept Lett. 2016;23(11):1024-1031. doi: 10.2174/0929866523666160901154216.
10
Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice.
Atherosclerosis. 2003 Jun;168(2):229-37. doi: 10.1016/s0021-9150(03)00101-1.

引用本文的文献

1
Peptides as Therapeutic Agents for Atherosclerosis.
Methods Mol Biol. 2022;2419:89-110. doi: 10.1007/978-1-0716-1924-7_6.
2
Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides.
PLoS One. 2017 Nov 20;12(11):e0188191. doi: 10.1371/journal.pone.0188191. eCollection 2017.
3
The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis.
Clin Lipidol. 2015 Jun;10(3):215-217. doi: 10.2217/clp.15.18.
4
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.
J Med Chem. 2014 Mar 27;57(6):2169-96. doi: 10.1021/jm4005847. Epub 2013 Oct 29.
5
Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats.
Biochem Biophys Res Commun. 2013 Jul 12;436(4):705-10. doi: 10.1016/j.bbrc.2013.06.020. Epub 2013 Jun 17.
6
7
Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.
Atherosclerosis. 2013 Mar;227(1):58-64. doi: 10.1016/j.atherosclerosis.2012.10.064. Epub 2012 Nov 2.
8
A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia.
Am J Physiol Heart Circ Physiol. 2013 Jan 15;304(2):H328-36. doi: 10.1152/ajpheart.00500.2012. Epub 2012 Nov 2.
9
Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
Atherosclerosis. 2012 Oct;224(2):326-31. doi: 10.1016/j.atherosclerosis.2012.05.040. Epub 2012 Jun 23.
10
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein.
Cardiol Res Pract. 2012;2012:148796. doi: 10.1155/2012/148796. Epub 2012 May 7.

本文引用的文献

1
Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2).
Atherosclerosis. 2010 Jan;208(1):134-41. doi: 10.1016/j.atherosclerosis.2009.07.019. Epub 2009 Jul 15.
2
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
J Lipid Res. 2007 Sep;48(9):1915-23. doi: 10.1194/jlr.R700010-JLR200. Epub 2007 Jun 14.
4
Synthetic peptides: managing lipid disorders.
Curr Opin Lipidol. 2006 Jun;17(3):233-7. doi: 10.1097/01.mol.0000226114.89812.75.
6
Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity.
J Biol Chem. 2004 Jun 18;279(25):26509-17. doi: 10.1074/jbc.M314276200. Epub 2004 Apr 8.
7
Protein measurement with the Folin phenol reagent.
J Biol Chem. 1951 Nov;193(1):265-75.
8
Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice.
Atherosclerosis. 2003 Jun;168(2):229-37. doi: 10.1016/s0021-9150(03)00101-1.
9
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
Circulation. 2002 Nov 12;106(20):2526-9. doi: 10.1161/01.cir.0000038419.53000.d6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验